Short-term androgen deprivation therapy does not improve survival in patients receiving postoperative radiotherapy for prostate cancer

1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse events were comparable between both groups and no fatalities were reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Short-term androgen deprivation therapy (ADT) with primary adjuvant radiotherapy is known to improve metastasis-free survival in patients

Related Keywords

Ireland ,Denmark ,Canada ,United Kingdom , ,Rating Level ,Castration Sensitive Prostate ,Between Nov ,